ACE2-based therapeutics could be used to treat other respiratory infections with ACE2-dependent cell entry mechanisms, such as those caused by SARS-CoV-1 and HCoV-NL63 coronaviruses (40, 41). Here, ACE2 is linked to respiratory tract infectious disorder.